Prestige Consumer Healthcare (NYSE:PBH) Price Target Raised to $104.00

Prestige Consumer Healthcare (NYSE:PBH) had its price objective hoisted by research analysts at DA Davidson from $95.00 to $104.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. DA Davidson’s price target indicates a potential upside of 18.07% from the stock’s current price.

A number of other research firms also recently commented on PBH. Sidoti downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research report on Monday, December 9th. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 24th. Finally, Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $87.50.

Prestige Consumer Healthcare Trading Up 0.8 %

Shares of PBH traded up $0.73 during trading on Friday, reaching $88.08. 141,122 shares of the company traded hands, compared to its average volume of 299,480. Prestige Consumer Healthcare has a twelve month low of $60.00 and a twelve month high of $88.03. The stock has a 50-day simple moving average of $79.19 and a 200-day simple moving average of $75.34. The stock has a market cap of $4.35 billion, a PE ratio of 21.37, a price-to-earnings-growth ratio of 2.15 and a beta of 0.50. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. On average, analysts anticipate that Prestige Consumer Healthcare will post 4.46 earnings per share for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the sale, the executive vice president now owns 18,365 shares of the company’s stock, valued at $1,505,930. The trade was a 33.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider William P’pool sold 8,987 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the sale, the insider now owns 20,058 shares in the company, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 38,810 shares of company stock worth $3,187,300. 1.60% of the stock is currently owned by insiders.

Institutional Trading of Prestige Consumer Healthcare

Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its position in shares of Prestige Consumer Healthcare by 3.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock worth $19,630,000 after buying an additional 8,533 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Prestige Consumer Healthcare by 4.0% in the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock valued at $95,678,000 after purchasing an additional 50,961 shares in the last quarter. Sequoia Financial Advisors LLC grew its position in shares of Prestige Consumer Healthcare by 12.9% in the third quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company’s stock valued at $708,000 after purchasing an additional 1,120 shares during the last quarter. Avior Wealth Management LLC increased its stake in shares of Prestige Consumer Healthcare by 1,570.7% during the 4th quarter. Avior Wealth Management LLC now owns 8,554 shares of the company’s stock worth $668,000 after purchasing an additional 8,042 shares in the last quarter. Finally, Barclays PLC raised its position in shares of Prestige Consumer Healthcare by 346.3% during the 3rd quarter. Barclays PLC now owns 92,444 shares of the company’s stock worth $6,665,000 after purchasing an additional 71,730 shares during the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.